MedTrace Logo

Contact Lenses With New UV-blocker Manufactured With Different Techniques

NCT03475875 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 92

Last updated 2019-06-04

Study results available
· View outcomes & findings →

Summary

This study is a randomized, 4-visit, double-masked, 2x3 bilateral crossover, dispensing trial. The study lenses will be worn as daily wear (DW) for a period of two weeks each with one of the study lenses being worn twice. Each study lens is expected to be worn at least five (5) days per week for at least six (6) hours per day worn. There will be no washout period between study lenses.

Conditions

  • Correction of Refraction Error
  • Attenuation of Bright Light

Interventions

DEVICE

senofilcon A TEST Lens

senofilcon A with new UV blocker investigational process

DEVICE

senofilcon A CONTROL Lens

senofilcon A with new UV blocker standard process

Sponsors & Collaborators

  • Johnson & Johnson Vision Care, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-02-19
Primary Completion
2018-04-18
Completion
2018-04-18
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03475875 on ClinicalTrials.gov